Patent 8075887 was granted and assigned to Regeneron Pharmaceuticals, Inc. on December, 2011 by the United States Patent and Trademark Office.
The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.